Mark P. Nicol mainly focuses on Tuberculosis, Mycobacterium tuberculosis, Internal medicine, Sputum and Immunology. His Tuberculosis research incorporates themes from Surgery, Drug resistance and Intensive care medicine. His Surgery study combines topics in areas such as Test and Clinical trial.
The study incorporates disciplines such as Genetics, Immune system, Virology, Real-time polymerase chain reaction and Virulence in addition to Mycobacterium tuberculosis. His Internal medicine study which covers Pulmonary tuberculosis that intersects with Laboratory service. The concepts of his Sputum study are interwoven with issues in Nucleic acid amplification technique, Randomized controlled trial, Rifampicin and Microbiology.
Mark P. Nicol mainly investigates Tuberculosis, Internal medicine, Mycobacterium tuberculosis, Sputum and Immunology. His work in Tuberculosis tackles topics such as Prospective cohort study which are related to areas like Disease. His Internal medicine research is multidisciplinary, incorporating elements of Carriage and Pulmonary tuberculosis.
His work deals with themes such as Rifampicin, Virology, Drug resistance, Microbiology and Intensive care medicine, which intersect with Mycobacterium tuberculosis. His study in Virology is interdisciplinary in nature, drawing from both GeneXpert MTB/RIF and Virulence. His study connects Tuberculin and Immunology.
His primary areas of investigation include Tuberculosis, Internal medicine, Lipoarabinomannan, Prospective cohort study and Sputum. His Tuberculosis research integrates issues from Diagnostic accuracy, Clinical trial and MEDLINE. His research on Internal medicine frequently links to adjacent areas such as Gastroenterology.
His Lipoarabinomannan research incorporates elements of Test, Tuberculous meningitis, Pre- and post-test probability, Urine and Urinary system. The various areas that Mark P. Nicol examines in his Prospective cohort study study include Pulmonary tuberculosis and Disease. The Mycobacterium tuberculosis study combines topics in areas such as Whole genome sequencing and Host immunity.
His primary scientific interests are in Tuberculosis, Internal medicine, Lipoarabinomannan, Urine and Sputum. His Tuberculosis study integrates concerns from other disciplines, such as Clinical trial and Disease. His Internal medicine study combines topics from a wide range of disciplines, such as Multiple drug resistance, Gastroenterology, Mycobacterium tuberculosis complex, Mycobacterium tuberculosis and Isoniazid.
His research in Lipoarabinomannan intersects with topics in Urine testing, Hiv patients, Urinary system, Disease burden and Malnutrition. His Urine research is multidisciplinary, relying on both Diagnostic accuracy, Point-of-care testing and Confidence interval. His biological study spans a wide range of topics, including Urinalysis, Prospective cohort study, Pre- and post-test probability, Meta-analysis and Point of care.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Rapid molecular detection of tuberculosis and rifampin resistance.
Catharina C. Boehme;Pamela Nabeta;Doris Hillemann;Mark P. Nicol.
The New England Journal of Medicine (2010)
Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study
Catharina C. Boehme;Mark P. Nicol;Mark P. Nicol;Pamela Nabeta;Joy S. Michael.
The Lancet (2011)
Variable host-pathogen compatibility in Mycobacterium tuberculosis.
Sebastien Gagneux;Kathryn DeRiemer;Tran Van;Midori Kato-Maeda.
Proceedings of the National Academy of Sciences of the United States of America (2006)
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study.
Ting Shi;David A. McAllister;Katherine L. O'Brien;Eric A. F. Simoes.
The Lancet (2017)
Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance
Stephen D Lawn;Mark P Nicol;Mark P Nicol.
Future Microbiology (2011)
Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis.
Anna Vassall;Sanne van Kampen;Hojoon Sohn;Joy S. Michael.
PLOS Medicine (2011)
Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study.
Mark P Nicol;Mark P Nicol;Lesley Workman;Washiefa Isaacs;Jacinta Munro.
Lancet Infectious Diseases (2011)
Screening for HIV-Associated Tuberculosis and Rifampicin Resistance before Antiretroviral Therapy Using the Xpert MTB/RIF Assay: A Prospective Study
Stephen D. Lawn;Sophie V. Brooks;Katharina Kranzer;Katharina Kranzer;Mark P. Nicol;Mark P. Nicol.
PLOS Medicine (2011)
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study
Susan E Dorman;Samuel G Schumacher;David Alland;Pamela Nabeta.
Lancet Infectious Diseases (2018)
Research capacity. Enabling the genomic revolution in Africa
Charles Rotimi;Akin Abayomi;Alash'le Abimiku;Victoria May Adabayeri.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: